Antoni Ribas
APLA Health(US)University of California, Los Angeles(US)USC Norris Comprehensive Cancer Center(US)
Publications by Year
Research Areas
CAR-T cell therapy research, Cancer Immunotherapy and Biomarkers, Melanoma and MAPK Pathways, Immunotherapy and Immune Responses, Cutaneous Melanoma Detection and Management
Most-Cited Works
- → Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation(2011)7,653 cited
- → PD-1 blockade induces responses by inhibiting adaptive immune resistance(2014)6,551 cited
- → Cancer immunotherapy using checkpoint blockade(2018)6,495 cited
- → Pembrolizumab versus Ipilimumab in Advanced Melanoma(2015)5,779 cited
- → Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy(2017)5,287 cited
- → Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma(2014)4,353 cited
- → IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade